Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OPK Stock Forecast 2026-2027
$1.17
Current Price
$898.21M
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to OPK Price Targets
+626.5%
To High Target of $8.50
+156.4%
To Median Target of $3.00
+19.7%
To Low Target of $1.40
OPK Price Momentum
+2.6%
1 Week Change
-1.7%
1 Month Change
-14.0%
1 Year Change
-7.1%
Year-to-Date Change
-26.9%
From 52W High of $1.60
+6.4%
From 52W Low of $1.10
📊 TOP ANALYST CALLS
Did OPK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if OPKO Health is one of their latest high-conviction picks.
Latest OPK Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, OPK has a bullish consensus with a median price target of $3.00 (ranging from $1.40 to $8.50). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.17, the median forecast implies a 156.4% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OPK Analyst Ratings
5
Buy
2
Hold
0
Sell
OPK Price Target Range
Low
$1.40
Average
$3.00
High
$8.50
Current: $1.17
Latest OPK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OPK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 2, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $1.50 |
| Nov 20, 2025 | JP Morgan | Brian Cheng | Neutral | Initiates | $N/A |
| Oct 31, 2025 | Jefferies | Maury Raycroft | Hold | Downgrade | $1.60 |
| Oct 30, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| May 1, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Apr 25, 2025 | JP Morgan | Eric Joseph | Neutral | Initiates | $N/A |
| Apr 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 12, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Mar 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Feb 28, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Jan 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $3.00 |
| Nov 8, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Sep 26, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Sep 20, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Sep 17, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Sep 17, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $3.00 |
| Aug 8, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $2.25 |
| Jul 18, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $3.00 |
Opko Health Inc. (OPK) Competitors
The following stocks are similar to OPKO Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Opko Health Inc. (OPK) Financial Data
Opko Health Inc. has a market capitalization of $898.21M with a P/E ratio of -3.9x. The company generates $606.88M in trailing twelve-month revenue with a -37.2% profit margin.
Revenue growth is -19.2% quarter-over-quarter, while maintaining an operating margin of -29.0% and return on equity of -17.1%.
Valuation Metrics
Market Cap
$898.21M
Enterprise Value
$928.07M
P/E Ratio
-3.9x
PEG Ratio
0.0x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
-19.2%
Gross Margin
+43.1%
Operating Margin
-29.0%
Net Margin
-37.2%
EPS Growth
-19.2%
Financial Health
Cash/Price Ratio
+41.0%
Current Ratio
4.0x
Debt/Equity
31.3x
ROE
-17.1%
ROA
-6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Opko Health Inc. (OPK) Business Model
About Opko Health Inc.
What They Do
Develops biopharmaceuticals and diagnostic services.
Business Model
OpKO Health Inc. generates revenue through two key segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals segment focuses on developing and commercializing innovative therapies for serious health conditions, while the Diagnostics segment offers clinical laboratory testing services, catering to a wide range of healthcare providers across the nation.
Additional Information
Founded in 1991 and headquartered in Miami, Florida, OpKO Health is committed to enhancing patient outcomes in the healthcare sector. The company collaborates with leading pharmaceutical firms to advance its product offerings and improve global health.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,275
CEO
Dr. Phillip Frost M.D., Ph.D.
Country
United States
IPO Year
1995
Website
www.opko.comOpko Health Inc. (OPK) Latest News & Analysis
Latest News
Quick Summary
OPK shows strength with RAYALDEE and partnerships, but faces revenue decline, losses, and dependence on one drug, impacting its near-term outlook.
Why It Matters
Revenue decline and losses raise concerns about OPK's financial health, while dependency on a single drug heightens risk, potentially affecting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
OPKO Health, Inc. (OPK) has released its Q4 2025 earnings call transcript, detailing financial performance and company updates for that quarter.
Why It Matters
OPKO Health's Q4 2025 earnings call provides insights into financial performance, future guidance, and strategic direction, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
OPKO Health, Inc. reported Q4 and full-year 2025 results and provided guidance for Q1 and 2026. Key highlight includes a research collaboration with Regeneron Pharmaceuticals.
Why It Matters
OPKO's collaboration with Regeneron may enhance its R&D capabilities, potentially leading to innovative therapies and increased revenue, impacting its stock performance and growth outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
OPKO Health (OPK) reported a quarterly loss of $0.04 per share, better than the estimated loss of $0.07, compared to a profit of $0.01 per share a year earlier.
Why It Matters
OPKO Health's smaller-than-expected loss indicates improved performance and potential for recovery, which may boost investor confidence and affect stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
OPKO Health's Q4 2025 financial results should be evaluated against Wall Street estimates and year-over-year metrics for a comprehensive performance analysis.
Why It Matters
Comparing OPKO Health's key metrics to Wall Street estimates and prior year values provides insights into growth, operational efficiency, and market expectations, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
OPKO Health reported Q4 earnings and revenue exceeding estimates; however, the company experienced a sales decline and a narrowing of gross margins.
Why It Matters
OPKO Health's earnings beat signals potential strength, but declining sales and narrowing gross margins raise concerns about future profitability, impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About OPK Stock
What is Opko Health Inc.'s (OPK) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Opko Health Inc. (OPK) has a median price target of $3.00. The highest price target is $8.50 and the lowest is $1.40.
Is OPK stock a good investment in 2026?
According to current analyst ratings, OPK has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OPK stock?
Wall Street analysts predict OPK stock could reach $3.00 in the next 12 months. This represents a 156.4% increase from the current price of $1.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Opko Health Inc.'s business model?
OpKO Health Inc. generates revenue through two key segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals segment focuses on developing and commercializing innovative therapies for serious health conditions, while the Diagnostics segment offers clinical laboratory testing services, catering to a wide range of healthcare providers across the nation.
What is the highest forecasted price for OPK Opko Health Inc.?
The highest price target for OPK is $8.50 from at , which represents a 626.5% increase from the current price of $1.17.
What is the lowest forecasted price for OPK Opko Health Inc.?
The lowest price target for OPK is $1.40 from at , which represents a 19.7% increase from the current price of $1.17.
What is the overall OPK consensus from analysts for Opko Health Inc.?
The overall analyst consensus for OPK is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are OPK stock price projections?
Stock price projections, including those for Opko Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:34 AM UTC